Pleural Diseases Therapeutics Market
Market Insights on Pleural Diseases Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Pleural Diseases Therapeutics Market by Treatment, End Users & Region | Forecast 2023 to 2033
Pleural Diseases Therapeutics Market Snapshot (2023 to 2033)
Expected to be valued at US$ 4.98 billion in 2023, the market for pleural diseases therapeutics is estimated to register a compounded annual growth rate (CAGR) of 6.5% from 2023 to 2033. According to Future Market Insights, the market is expected to reach US$ 9.4 billion by the end of the said forecast period.
The pleural effusions treatment market growth is expected to be driven by the increasing number of medical cases related to congestive heart failure, Pneumonia, lung cancer, and tuberculosis. For example, In Germany, the total number of pleural disease cases registered per year ranges from 4 to 5 million. This is an indication of how prevalent the disease is and if left undiagnosed may result in death. Similarly, lung cancer is also a common disease around the globe which has been following a surging trend in the last few years. As per reports submitted by American Lung Association, in 2018, around 13.2% of the diagnosed cancer cases were related to lung cancer.
Moreover, 2.3 million new cases of lung cancer were registered in 2022, whereas the country suffered over 1.3 million deaths pertaining to lung cancer. Some of other reasons for the high prevalence of lung cancer include the increasing exposure to second-hand smoke, along with radon gas, asbestos, or other carcinogens. These factors along with rising prevalence of congestive heart failure and other heart and lung conditions are driving growth of Pleural disease therapeutics market during the forecast period.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 4.98 billion |
|
Anticipated Forecast Value (2033) |
US$ 9.4 billion |
|
Projected Growth Rate (2023 to 2033) |
CAGR 6.5% |
Let us know your requirement to get
100% FREE customization
2018 to 2022 Pleural Diseases Therapeutics Demand Analysis vs. Forecast 2023 to 2033
The market for Pleural diseases therapeutics was worth US$ 3.8 billion in 2018, while growing at a CAGR of 5.5% during the historical period. Since pleural effusions are very common and can occur as a result of different main causes, the market is going through an increasing research trend on understanding the root causes and effective treatment for the medical condition. This will open up new avenues for market expansion of pleural disease treatment.
The European Respiratory Journal reported that malignant pleural effusions are more prevalent in patients suffering from neoplastic diseases. According to their report, from the total number of patients who died with malignancies, around 15% were detected with malignant effusions. Moreover, the increasing interest of the healthcare sector in learning about the virus is anticipated to present various opportunities for market expansion. Similarly, growing rate of research and development initiatives will drive the market growth.
Also, rising ongoing clinical trials being carried out by many pharmaceuticals’ companies, increasing healthcare outcomes, and surging incidences of pleural effusion linked with other chronic conditions are some of the significant factors among others propelling pleural effusion drug market growth in the coming years. Furthermore, increasing technological advancements and modernization in the healthcare devices and rising demand from emerging economies will further create new opportunities for the pleural effusion drug market in the forecast period of 2023 to 2033.
Which are Some Prominent Drivers of the Pleural disease therapeutics market?
Growing Investments and Adoption of New Treatment Techniques to fuel Market Growth
The increasing number of people suffering from pleural effusions around the globe is expected to drive growth of pleural effusions treatment market. Rising need for effective procedures for the treatment and early diagnosis is going to augment market growth. Furthermore, increase in number of acquisition strategies and company collaborations are expected to fuel market growth. Also, increasing prevalence of congestive heart failure, and other heart conditions, pneumonia, lung conditions, cancer, and tuberculosis, and increase in the number of research and development activities are further expected to augment market growth.
On the other hand, surging investments, rising healthcare expenditure, growing population, development in technology, and increasing awareness regarding treatment of Pleural effusion is expected to positively influence pleural disease treatment market. Furthermore, growing demand for novel medication and increasing multidisciplinary interest in this field is anticipated to extend lucrative opportunities to the market players which will positively benefit the market. Additionally, rising utilization of thoracic ultrasonography, pleurodesis agents, the intrapleural fibrinolytics, or the latest pleural drainages techniques for the treatment of Pleural diseases is projected to propel market growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Projected to be Faced by the Market?
A Dearth of Skilled Professionals restraining Market Expansion
The emerging economies are extremely underfunded as compared to the demand for developed healthcare infrastructure. There is a shortage of adequate skilled medical staff to meet the rising healthcare demands of the population. Additionally, the absence of sufficient healthcare facilities and attractive medical reimbursement policies are expected to restrain emerging economies from achieving full potential in the healthcare sector.
This will challenge market expansion of pleural disease therapeutics. Furthermore, high risk of infection, collapsed lung and bleeding are also expected to restrain the Pleural diseases therapeutics market during the forecast period.
Region-Wise Insights
What are the growth prospects in North America?
North America to dominate the market with maximum share
North America is anticipated to dominate the market of Pleural treatment by reaching market value of US$ 4.23 billion by end of the forecast period. It is estimated to have monopoly over 45% market share by 2033, while exhibiting CAGR of 6.2% during the forecast period. Among other countries in this region, the United States is expected to dominate the market, owing to factors such as rising healthcare expenditure, mounting research and developments, and increasing prevalence of heart diseases. In addition, increase in geriatric population across the United States is also expected to propel growth in pleural effusions market.
In patients with cancer and heart failure, pleural effusions are most likely malignant that increases the market scope of pleural disease therapeutics. The rising burden of diseases in this region is anticipated to create opportunities for expansion of pleural disease treatment market. Moreover, the data shared by the American Cancer Society’s Cancer Statistics in 2022, around 2.5 million new cancer cases are expected to be diagnosed in the United States in the year 2023 which will open up new paths for market expansion of pleural disease treatment.
On the other hand, heart failure is a prevalent health and economic burden for the United States due to the aging population. As per the American Heart Association data provided in April 2022, nearly 116 million people suffer from hypertension, 100 million have obesity, 92.2 million have prediabetes, 26.5 million have diabetes, and around 125 million have atherosclerotic cardiovascular diseases in the United States, which are the risk factors for the development of heart failure. Therefore, the growing burden of cardiovascular diseases creates the risk of pleural effusions in the target population in this region. This is expected to fuel market growth during the projected period.
Similarly, increasing technological advancements, the availability of structured healthcare facilities, and increasing prevalence of respiratory diseases are also expected to fuel market growth. According to the American Cancer Society, lung cancer was most prevalent cancer in the United States in 2018. It is the second most prevalent cancer in both men and women. Also, it is the most common cause of malignant pleural effusion, accounting for around 30% of all Malignant pleural effusion. This will bolster the market growth of therapeutics used in treating pleural diseases, which will further support market growth.
What is the growth outlook in Europe?
High rate of Chronic Lung Disorders propelling growth in Europe
The market for pleural disease therapeutics in Europe is projected to hold around 29% market share. The regional market is estimated to be worth more than US$ 2.7 billion by end of 2033, with a CAGR of 5.5% during the projected period. This region is the second largest market for treatment of Pleural diseases globally, followed by Asia Pacific. The growth is attributable to increase in prevalence of chronic lung conditions and cancer diseases leading to pleural effusion state. This is a significant factor driving growth in this region. Furthermore, presence of key players and the availability of expertise in performing surgeries are major factors propelling growth in this region.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category wise Insights
By Treatment, which Segment will possess Market Dominance?
Thoracentesis driving growth with a Significant Market Share
This segment is estimated to dominate the market by accounting for 34% market by end of the forecast period. The treatment of pleural diseases by utilizing Thoracentesis treatment is gaining traction and it is showing opportunities prospects in the coming years. It used in case of large effusions whereas pleurodesis can prevent pleural effusions from coming back.
In the United States, thoracentesis is performed more than 1.75 million times a year which reflects the growth potential of this segment in the coming years. Also, this treatment option helps the affected patients in easing any shortness of breath or pain by removing the fluid and relieving pressure from the lungs. Moreover, rising inclination from patients and recommendation from doctors in treating pleural effusion by this procedure is propelling growth of this segment.
By End User, which Segment is most likely to dominate the Market?
Hospitals to stimulate growth with Maximum Share
Hospitals are expected to lead the segment by reaching 65% market share by end of the forecast period. The surge in investments by industry players in pleural disease therapeutics market is directly benefiting the hospitals, owing to robust infrastructure, next generation medical equipment’s, rapid adoption of novel drugs and ease of access to the patients. These factors are fuelling growth of this segment.
Start-ups in Pleural Diseases Therapeutics Market
Start-ups help in understanding the growth prospects of any industry. Start-ups also have the potential to generate high returns which directly benefits in growth of any market. This is because these are naturally more efficient at converting inputs into outputs. These are more flexible and adaptable in nature, able to shift rapidly in response to changing market conditions. Some of the start-ups that will fuel the expansion of Pleural disease therapeutics market are:
- TDL Innovations is a Princeton, United States-based developer of medical technologies which has expertise in treating malignant pleural effusion. The company has developed a delivery system to access the pleural region to provide treatment. It was founded in 2014.
- Oxipit is a Vilnius, Lithuania-based start-up that was incepted in 2017. This start-up offers Artificial intelligence-based medical image analysis for doctors. Solutions offered by this company include ChestGlass, ChestEye, and QEye. ‘ChestGlass’ is a solution that provides radiographs for comparison, to analyze the anomalies. It also provides computer-aided diagnosis solution that analyses chest X-ray radiographs and provides information about enlarged heart, edema, pleural effusion, subcutaneous emphysema and others. Likewise, QEye is a solution that prioritizes patients with a high risk in the queue of report analysis. This start-up also offers automatic analysis of brain lesions in head MRI scans. The company was granted funding of USD 2 million from Practica Capital, CoInvest Capital, EIT Health and 2 Other Investors
- Sensorium Lab is a Polish company which offers a user-friendly and non-invasive diagnostic system for assessment of pleural effusion. The device makes it possible to monitor patients remotely. The monitoring can easily be handled by non-professionals also which makes this system ease to handle.
Market Competition
The Pleural diseases therapeutics market is moderately competitive and consists of various key market players. These players are creating novel delivery systems for treating Pleural diseases. This is anticipated to fuel Pleural diseases therapeutics market. The key players in the market are: WakeMed Health and Hospitals, Boston Medical, Max Healthcare, Avik Pharma, Pfizer CentreOne, Hovione, Pipelinepharma, Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., Sanofi S.A.
Key market players are focusing on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to enhance their product portfolio. This is expected to propel the global Pleural diseases therapeutics market.
Some Recent Developments in the Market Are:
- In September 2021, Bristol Myers Squibb announced three-year data from the Checkmate -743 trial. According to the clinical trial data, serious adverse reactions occurred in almost 54% of patients receiving OPDIVO plus YERVOY. The most frequent serious adverse reactions reported in ≥2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis, pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism.
- In January 2020, Argon Medical launched single and triple loop retrieval kits for its USA market with the aim to improve lives of patients. The products have managed to secure the approval from the United States Food and Drug Administration, and are efficient in the removal of retrievable IVC filters with the help of a jugular approach. These single and triple loop retrieval kits are the only 2 kits to have received FDA approval in terms of any retrievable IVC filter from a jugular approach.
- In May 2021, the FDA approved first-of-its-kind targeted therapy for lung cancer mutation which was up until now considered drug resistant. The therapy is known as Lumakras (sotorasib) and will be used for adult patients who have non-small cell lung cancer where the tumor has genetic mutation called KRAS G12C and patients should have undergone at least one systemic therapy.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 4.98 billion |
|
Market Value in 2033 |
US$ 9.4 billion |
|
Growth Rate |
CAGR of 6.5% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Pleural Diseases Therapeutics Industry Survey
By Treatment:
- Drug Class
- Antibiotics
- Antifungals
- Corticosteroids
- Narcotic Analgesics
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Bullectomy
- Chemotherapy
- Video-Assisted Thorascopic Surgery (VATS)
- PleurX Catheter
- Pleurodesis Therapy
- Radiation Therapy
- Thoracentesis
- Thoracostomy
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
FMI projects the global Pleural diseases therapeutics market to expand at a 6.5% value CAGR by 2033.
The global pleural diseases therapeutics market is expected to garner a market value of US$ 9.4 billion by 2033.
FMI has projected North America to be one of the most lucrative regions for Pleural diseases therapeutics market.
Asia Pacific is anticipated to grow the fastest during the forecast period.
Thoracentesis is expected to dominate the market by treatment during the forecast period
Hospitals are projected to lead the market with maximum share by end of the forecast period
The market value of Pleural diseases therapeutics market was worth USD 3.8 billion in 2018.
The market in North America is projected to account for 45% market share by end of the forecast period.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Drug Class
5.3.1.1. Antibiotics
5.3.1.2. Antifungals
5.3.1.3. Corticosteroids
5.3.1.4. Narcotic Analgesics
5.3.1.5. Nonsteroidal Anti-inflammatory Drugs - NSAIDs
5.3.2. Bullectomy
5.3.3. Chemotherapy
5.3.4. Video-Assisted Thorascopic Surgery - VATS
5.3.5. PleurX Catheter
5.3.6. Pleurodesis Therapy
5.3.7. Radiation Therapy
5.3.8. Thoracentesis
5.3.9. Thoracostomy
5.3.10. Tumor Ablation
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End Users
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Treatment
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End Users
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. WakeMed Health and Hospitals
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Boston Medical Center
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Max Healthcare
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Avik Pharma
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Pfizer CentreOne
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Hovione
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Pipelinepharma
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Hoffmann-La Roche AG
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Boehringer Ingelheim International GmbH
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Bausch Health Companies Inc.
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. Sanofi S.A.
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Table 16: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Middle East and Africa Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: Middle East and Africa Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End Users, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End Users, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End Users, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End Users, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End Users, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End Users, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End Users, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by End Users, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by End Users, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: Middle East and Africa Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: Middle East and Africa Market Value (US$ Million) by End Users, 2023 to 2033
Figure 78: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: Middle East and Africa Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: Middle East and Africa Market Value (US$ Million) Analysis by End Users, 2018 to 2033
Figure 86: Middle East and Africa Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033
Figure 87: Middle East and Africa Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033
Figure 88: Middle East and Africa Market Attractiveness by Treatment, 2023 to 2033
Figure 89: Middle East and Africa Market Attractiveness by End Users, 2023 to 2033
Figure 90: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
